Statement Of Changes In Equity [Abstract]

GenSight Biologics S.A. - Filing #2813015

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity	15,279,000 EUR	—	—	170,024,000 EUR	27,625,000 EUR	—	181,211,000 EUR	1,158,000 EUR	—	—	28,617,000 EUR	15,989,000 EUR	137,726,000 EUR	—	—	—	181,175,000 EUR	—	1,158,000 EUR	—	1,022,000 EUR	34,015,000 EUR	108,034,000 EUR	152,776,000 EUR	11,749,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)	—	—	27,625,000 EUR	—	—	—	—	—	27,625,000 EUR	—	—	—	—	28,617,000 EUR	—	—	—	—	—	28,617,000 EUR	—	—	—	—	—
Comprehensive income	—	—	27,748,000 EUR	—	—	124,000 EUR	—	—	27,625,000 EUR	—	—	—	—	28,617,000 EUR	207,000 EUR	—	—	—	—	28,824,000 EUR	—	—	—	—	—
Issue of equity	—	1,000 EUR	0 EUR	—	—	—	—	—	—	1,000 EUR	—	—	—	—	—	29,877,000 EUR	—	123,000 EUR	—	30,000,000 EUR	—	—	—	—	—
Increase (decrease) through treasury share transactions, equity	—	—	193,000 EUR	—	—	193,000 EUR	—	—	—	—	—	—	—	—	305,000 EUR	—	—	—	—	305,000 EUR	—	—	—	—	—
Increase (decrease) through share-based payment transactions, equity	—	—	3,364,000 EUR	—	—	3,364,000 EUR	—	—	—	—	—	—	—	—	4,834,000 EUR	—	—	—	—	4,834,000 EUR	—	—	—	—	—